IRIS
BERTOLI, ADA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.380
EU - Europa 3.513
AS - Asia 3.355
SA - Sud America 506
Continente sconosciuto - Info sul continente non disponibili 385
AF - Africa 69
OC - Oceania 10
Totale 33.218
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.184
SG - Singapore 1.493
IT - Italia 708
CN - Cina 663
DE - Germania 433
BR - Brasile 401
RU - Federazione Russa 380
SE - Svezia 379
UA - Ucraina 296
HK - Hong Kong 272
FR - Francia 264
PL - Polonia 262
VN - Vietnam 239
IE - Irlanda 227
KR - Corea 227
FI - Finlandia 198
GB - Regno Unito 181
BD - Bangladesh 157
CA - Canada 98
JP - Giappone 80
NL - Olanda 54
IN - India 43
MX - Messico 38
AR - Argentina 33
ID - Indonesia 28
AT - Austria 22
ES - Italia 21
TR - Turchia 21
ZA - Sudafrica 21
CZ - Repubblica Ceca 20
IQ - Iraq 20
JM - Giamaica 20
CO - Colombia 17
BE - Belgio 15
EC - Ecuador 14
PH - Filippine 14
CL - Cile 13
UZ - Uzbekistan 13
CH - Svizzera 12
CR - Costa Rica 10
IL - Israele 10
PK - Pakistan 10
VE - Venezuela 10
AU - Australia 9
EG - Egitto 9
JO - Giordania 9
DK - Danimarca 8
KG - Kirghizistan 8
PY - Paraguay 8
KE - Kenya 7
AE - Emirati Arabi Uniti 6
EE - Estonia 6
ET - Etiopia 6
EU - Europa 6
HN - Honduras 6
MA - Marocco 6
NG - Nigeria 6
NI - Nicaragua 5
NP - Nepal 5
TT - Trinidad e Tobago 5
BG - Bulgaria 4
GT - Guatemala 4
IR - Iran 4
LT - Lituania 4
MY - Malesia 4
OM - Oman 4
PE - Perù 4
RO - Romania 4
SA - Arabia Saudita 4
CY - Cipro 3
DZ - Algeria 3
KZ - Kazakistan 3
PR - Porto Rico 3
PT - Portogallo 3
SV - El Salvador 3
TH - Thailandia 3
TN - Tunisia 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
AZ - Azerbaigian 2
BO - Bolivia 2
GY - Guiana 2
HU - Ungheria 2
LY - Libia 2
MN - Mongolia 2
MT - Malta 2
SC - Seychelles 2
UY - Uruguay 2
AO - Angola 1
BW - Botswana 1
BY - Bielorussia 1
BZ - Belize 1
CM - Camerun 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GE - Georgia 1
GR - Grecia 1
LB - Libano 1
LC - Santa Lucia 1
Totale 32.832
Salva come PNG Salva come JPEG
Città #
Woodbridge 6.679
Wilmington 6.057
Houston 4.717
Singapore 915
Ashburn 743
Fairfield 715
Chandler 589
Ann Arbor 528
San Jose 501
Seattle 305
Hong Kong 267
Beijing 265
Jacksonville 242
Rome 232
Kraków 231
Cambridge 229
Council Bluffs 223
Dublin 210
Santa Clara 172
New York 171
Medford 156
Los Angeles 138
Helsinki 123
Dearborn 112
The Dalles 106
Zhengzhou 76
Lawrence 74
Milan 74
Tokyo 71
Hanoi 70
Ho Chi Minh City 61
Dallas 60
Moscow 56
San Diego 55
Buffalo 51
Denver 46
Munich 46
São Paulo 44
Lauterbourg 41
North Bergen 40
Boardman 38
Orem 38
Phoenix 38
Menlo Park 36
Mülheim 35
Nuremberg 32
Atlanta 30
Montreal 27
San Francisco 26
London 25
Palo Alto 25
Chicago 24
Brooklyn 22
Warsaw 21
Creede 20
Jakarta 19
Colorado Springs 18
Columbus 18
Redondo Beach 18
Chennai 17
Falls Church 16
Shanghai 16
Stockholm 15
University Park 15
Amsterdam 14
Brussels 14
Frankfurt am Main 14
Guangzhou 14
Kingston 14
Nanjing 14
New Orleans 14
Olomouc 14
Bari 13
Naples 13
Rio de Janeiro 13
Haiphong 12
Lappeenranta 12
Toronto 12
Boston 11
Johannesburg 11
Norwalk 11
Mexico City 10
Palermo 10
Quito 10
Tashkent 10
Verona 10
Amman 9
Belo Horizonte 9
Brasília 9
Dong Ket 9
Las Vegas 9
Miami 9
Paris 9
Salvador 9
Turin 9
Vancouver 9
Vienna 9
Manchester 8
Redwood City 8
Seoul 8
Totale 26.473
Salva come PNG Salva come JPEG
Nome #
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 594
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors 555
Occupational HIV infection in a research laboratory with unknown mode of transmission: a case report 545
Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy 531
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 529
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients 526
Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso 526
Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child 515
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice 506
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 506
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia 502
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. 501
Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains 500
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 493
Altered deoxyribonucleotide pools in T-lymphoblastoid cells expressing the multisubstrate nucleoside kinase of Drosophila melanogaster 487
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development 484
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors 484
Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study 484
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. 483
A case of Italian HIV-2 infection: a genetic analysis 482
Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy 482
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 481
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 478
Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection 475
Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed 468
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen 466
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 460
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment 459
Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine 457
Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure 453
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group 449
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. 449
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group 447
Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy 444
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance 441
Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo 439
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy 434
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study 434
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA 434
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 432
The contribution of oxidative stress in apoptosis of human-cultured astroglial cells induced by supernatants of HIV-1-infected macrophages 432
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 431
Overlapping structure of HBV genome and immune selection pressure are critical forces modulating HBV evolution 427
Overlapping Structure of HBV genome and immune selecting pressure are the main driving forces for HBV evolution 426
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations 426
Temporal change in the use of genotypic resistance testing over the years 1999--2003 424
Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels 415
Genotypic tropism testing in HIV-1 proviral DNA can provide useful information at low-level viremia 412
Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome 409
Plasma HIV RNA decline and emergence of drug resistance mutations among patients with multiple virologic failures receiving resistance testing-guided HAART 405
Novel reverse transcriptase mutations specifically associated with selected anti-Hbv treatment can induce alterations and stop-codons in Hbv S antigen 402
Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen 396
HIV-1 non-B subtypes in Italy: a growing trend 395
Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 are specifically associated with dual tropism and modulate the interaction with CCR5 N-terminus 392
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection 388
Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14 387
The Lowest X4 Geno2Pheno-False Positive Rate Is Associated with Greater CD4-Depletion 383
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 381
Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy 373
The V118I mutation as a marker of advanced HIV infection and disease progression 367
Total HIV-1 DNA detection and quantification in peripheral blood by COBAS®AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0 364
null 357
Recent transmission clustering of HIV-1 C and CRF17-BF strains characterized by NNRTI-related mutations among newly diagnosed men in central Italy 338
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 318
A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in Vitro 284
HIV MDR is still a relevant issue despite its dramatic drop over the years 266
Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment 228
Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients 202
Comparison of Different HIV-1 Resistance Interpretation Tools for Next-Generation Sequencing in Italy 193
Cryptic HBV replicative activity is frequently revealed in anti-HBC-positive/hbsag-negative patients with HIV infection by highly sensitive molecular assays, and can be predicted by integrating classical and novel serological HBV markers 192
Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection 184
Long-term SARS-CoV-2 infection associated with viral dissemination in different body fluids Including bile in two patients with acute cholecystitis 168
HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21 163
Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals 160
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b 151
An HIV Type 2 Case Series in Italy: A Phylogenetic Analysis 150
HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation 138
Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings 129
Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease 129
Prevalence of hepatitis D virus infection in Central Italy has remained stable across the last 2 decades with dominance of subgenotypes 1 and characterized by elevated viral replication 125
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice 121
Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies 115
Prevalence and phenotypic susceptibility to doravirine of the HIV-1 reverse transcriptase V106I polymorphism in B and non-B subtypes 102
Stable temporal trend of HDV seroprevalence in central Italy across the last two decades with the circulation of HDV sub-genotypes 1 inducing different inflammatory stimuli 100
Infection Rate of Respiratory Viruses in the Pandemic SARS-CoV-2 Period Considering Symptomatic Patients: Two Years of Ongoing Observations 98
Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings 98
Evaluation of HIV-1 integrase variability by combining computational and probabilistic approaches 90
Factors predictive of multinucleoside analogue-resistance mutations in an unselected cohort of HAART-failed patients. 86
Genetic heterogenicity of HIV-1 protease in drug-naive and drug-treated HIV-positive patients 83
Factors predictive of virological response after genotyping resistance test (GRT): data from an unselected cohort 78
Cross-resistance among NNRTIs: evaluation of the option of recycling Efavirenz after Nevirapine failure 74
Identification of the Minimal Conserved Structure of the HIV-Reverse Transcriptase under the Presence and Absence of Drug Pressure 65
Comparison of diagnostic performances of HDV-RNA quantification assays used in clinical practice: Results from a national quality control multicenter study 65
Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation 53
Time to detection and loss of M184 genotypic mutation among HIV patients treated with 3TC and failing an HAART regimen 52
Temporal characterization of frequency of drug-resistance associated mutations in the HIV-1 protease and reverse transcriptase 51
A high degree of genetic variability characterises HDV sub-genotypes 1 and can drive the selection of divergent genetic pathways modulating HDV replicative potential and cytolytic activity. 48
Evaluation of HIV-1 transmitted drug-resistance among subtypes circulating from 2022 to 2024 in Italy: a refined analysis through next-generation sequencing 45
HDV sub-genotype 1 is characterized by increased genetic variability, which can promote the emergence of divergent genetic pathways that modulate HDV replicative potential and cytolytic activity. 38
Development of a Next-Generation Sequencing Protocol for Assessing Lenacapavir Resistance in HIV-1 Capsid 37
Totale 33.124
Salva come PNG Salva come JPEG
Categoria #
all - tutte 81.701
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 81.701
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022869 0 0 0 65 33 88 46 40 207 81 44 265
2022/20231.445 119 136 113 186 104 288 87 138 117 47 76 34
2023/2024437 57 10 30 20 45 98 22 20 10 20 5 100
2024/20252.321 92 501 243 116 99 132 299 120 258 134 152 175
2025/20264.276 315 149 399 386 391 177 577 508 506 392 246 230
2026/20271.758 252 235 759 512 0 0 0 0 0 0 0 0
Totale 33.218